Where Will Novavax Be in 1 Year?
What a difference a few months make. Vaccine specialist (NASDAQ: NVAX) started the year poorly, continuing with the issues it has encountered since mid-2021.
Those headwinds included the difficulties it faced in launching its COVID vaccine in the U.S. and the significant slowdown in demand for these products, leading to a decline in revenue and earnings for the biotech.
However, several developments have jolted Novavax's stock since January. The company's shares are up by just under 200% this year. Can it keep up that momentum through the next 12 months? Let's find out.
Source Fool.com
Novavax Inc. Stock
Our community is currently high on Novavax Inc. with 8 Buy predictions and 3 Sell predictions.
With a target price of 11 € there is a hugely positive potential of 54.28% for Novavax Inc. compared to the current price of 7.13 €.


